Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
27 Results for "
O-GlcNAcase
" in MedChemExpress (MCE) Product Catalog:
Products (27)
27 Results for "O-GlcNAcase" in MCE Product Catalog:
56
6
6 Cited Publications
Target:
Research Areas:
(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form .
1
1 Cited Publications
Target:
Research Areas:
MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration .
Synonyms: LY3372689
Target:
Research Areas:
Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease .
Synonyms: ASN90
Target:
Research Areas:
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .
Target:
Synonyms: O-GlcNAcase-IN-1
Target:
Research Areas:
TP-040 (O-GlcNAcase-IN-1), a chemical probe, is a potent and novel OGA inhibitor with an IC50 value of 46 nM.
Cat. No.: HY-176852
CAS No.: 2760514-33-6
Target:
Research Areas:
O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research .
Cat. No.: HY-P4752
CAS No.: 2022974-40-7
Target:
Research Areas:
Cat. No.: HY-149552
CAS No.: 67561-97-1
Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer .
Cat. No.: HY-P3795
CAS No.: 361443-81-4
Target:
Research Areas:
Cat. No.: HY-E71360
Target:
Research Areas:
O-GlcNAcase, Clostridium perfringens is a glycosidase derived from Clostridium perfringens, which functions in bacterial nutrient metabolism, host interaction and virulence regulation. O-GlcNAcase is a core enzyme in the cellular signal regulatory network and serves as a key target for various major and chronic diseases. O-GlcNAcase, Clostridium perfringens can be used for basic research and drug development of O-GlcNAcase due to its high conservation in catalytic mechanism and structure with human-derived enzymes .
Cat. No.: HY-145934B
CAS No.: 608514-41-6
Target:
Research Areas:
UDP-GlcNAz is the analogue of UDP-GlcNAc disodium (HY-112174). UDP-GlcNAc disodium is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc disodium is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
Cat. No.: HY-144682
CAS No.: 3085990-58-2
Target:
Research Areas:
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease .
Cat. No.: HY-181600
Target:
Research Areas:
O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor with an IC50 of 11.59 nM. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders .
Cat. No.: HY-161953
Target:
Research Areas:
O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects .
Cat. No.: HY-178510
Target:
Research Areas:
JQ1-S (GlcNAc) Cq is a sugar-modified BRD4 PROTAC degrader with a DC50 of 2.1 μM. JQ1-S (GlcNAc) Cq inhibits the formation of the ternary complex between CRBN and BRD4 (BD1/BD2). JQ1-S (GlcNAc) Cq serves as a substrate for O-GlcNAcase, which cleaves its O-GlcNAc domain to restore binding ability with CRBN, thereby forming a BRD4-containing ternary complex and triggering ubiquitination and proteasomal degradation of BRD4. JQ1-S (GlcNAc) Cq is applicable for cancer research .
Cat. No.: HY-183557
CAS No.: 2407072-65-3
Target:
Research Areas:
O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
